Biote Reports Fourth Quarter and Full Year 2024 Financial Results

About this update from Biote Corp.

[{"type":"text","content":"Strengthened business with launch of BioteRx and enhancements to Biote Method","length":77,"tagName":"p","attribs":{}},{"type":"text","content":"Provides fiscal 2025 outlook","length":28,"tagName":"p","attribs":{}},{"type":"text","content":"IRVING, Texas, March 12, 2025--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024.","length":304,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period)","length":115,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $49.8 million","length":24,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Procedure revenue of $36.6 million","length":34,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Gross profit margin of 71.8%","length":28,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to net income of $12.1 million and diluted earnings per share attributable to biote Corp. stockholders of $0.18","length":229,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Adjusted EBITDA1 of $15.1 million and Adjusted EBITDA margin1 of 30.3%","length":70,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":385,"olType":false},{"type":"text","content":"Full Year 2024 Financial Highlights (All financial result comparisons made are against the prior year)","length":103,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $197.2 million, an increase of 6.4%","length":46,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Procedure revenue of $150.3 million","length":35,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Gross profit margin of 70.5%","length":28,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Net income of $0.05 million and diluted earnings per share attributable to biote Corp. stockholders of $0.09 per diluted share, compared to net loss of $(2.8) million and diluted earnings per share att...

More updates from Biote Corp.